Log in
OTCMKTS:KHRNF

Khiron Life Sciences Stock Forecast, Price & News

$0.35
0.00 (0.00 %)
(As of 09/29/2020 12:00 AM ET)
Add
Compare
Today's Range
$0.34
Now: $0.35
$0.36
50-Day Range
$0.34
MA: $0.38
$0.43
52-Week Range
$0.22
Now: $0.35
$0.98
Volume52,489 shs
Average Volume171,227 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Khiron Life Sciences Corp. develops cannabis products for medical purposes. It also provides cosmeceutical and nutraceutical products. The company was founded in 2017 and is headquartered in Toronto, Canada.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 3.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.44 out of 5 stars


Industry, Sector and Symbol

Industry Drug Manufacturers - Specialty & Generic
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:KHRNF
CUSIPN/A
CIKN/A
Phone705-527-3564

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable
$0.35
0.00 (0.00 %)
(As of 09/29/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive KHRNF News and Ratings via Email

Sign-up to receive the latest news and ratings for KHRNF and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Khiron Life Sciences (OTCMKTS:KHRNF) Frequently Asked Questions

How has Khiron Life Sciences' stock price been impacted by COVID-19?

Khiron Life Sciences' stock was trading at $0.4259 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, KHRNF stock has decreased by 17.2% and is now trading at $0.3528.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Khiron Life Sciences?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Khiron Life Sciences in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Khiron Life Sciences
.

What price target have analysts set for KHRNF?

1 Wall Street analysts have issued 1-year target prices for Khiron Life Sciences' shares. Their forecasts range from $2.80 to $2.80. On average, they anticipate Khiron Life Sciences' share price to reach $2.80 in the next year. This suggests a possible upside of 693.7% from the stock's current price.
View analysts' price targets for Khiron Life Sciences
.

Are investors shorting Khiron Life Sciences?

Khiron Life Sciences saw a increase in short interest in September. As of September 15th, there was short interest totaling 143,800 shares, an increase of 32.7% from the August 31st total of 108,400 shares. Based on an average daily trading volume, of 188,200 shares, the short-interest ratio is presently 0.8 days.
View Khiron Life Sciences' Short Interest
.

Who are some of Khiron Life Sciences' key competitors?

Who are Khiron Life Sciences' key executives?

Khiron Life Sciences' management team includes the following people:
  • Mr. Alvaro Francisco Torres, Founder, CEO & Director (Age 40)
  • Mr. Andres Galofre, Co-founder & VP of Bus. Devel.s (Age 37)
  • Mr. Darren Collins, CFO & Corp. Sec. (Age 36)
  • Dr. Paulo Vega, VP of Medical (Age 54)
  • Mr. Chris Naprawa, Pres (Age 48)

What is Khiron Life Sciences' stock symbol?

Khiron Life Sciences trades on the OTCMKTS under the ticker symbol "KHRNF."

How do I buy shares of Khiron Life Sciences?

Shares of KHRNF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Khiron Life Sciences' stock price today?

One share of KHRNF stock can currently be purchased for approximately $0.35.

What is Khiron Life Sciences' official website?

The official website for Khiron Life Sciences is www.khiron.ca.

How can I contact Khiron Life Sciences?

The company can be reached via phone at 705-527-3564.

This page was last updated on 9/30/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.